Should You Buy Bristol-Myers Squibb Co (BMY) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
54.620
1 Day change
-1.69%
52 Week Range
62.650
Analysis Updated At
2026/01/28
Buy for a long-term investor. At ~$55, BMY is in a consolidation zone near key support (S1 ~$53.95) with improving fundamentals (Q3 2025 profit/EPS surge) and a clearly improving Wall Street outlook (multiple target raises + notable upgrades). Near-term sentiment is mixed (insider + Congress selling, slightly bearish options volume), but for a beginner long-term investor with $50k–$100k who wants to act now, the risk/reward favors starting a position at current levels rather than waiting for a perfect entry.
Technical Analysis
Price/Trend: BMY is trading around $55.08, sitting near the pivot level (55.283) with nearby support at ~53.95 and resistance at ~56.62. This suggests a range-bound market rather than a strong trend.
Momentum: MACD histogram is negative (-0.249) but contracting, which often indicates downside momentum is weakening.
RSI: RSI(6) ~52.9 (neutral), consistent with consolidation.
Moving averages: Converging MAs reinforce a “base-building”/sideways setup.
Near-term probability read: Pattern-based stats imply mild weakness over the next week (-1.58%) but positive skew over the next month (+3.76%). Overall, technicals support a patient long-term buy/accumulate rather than a short-term breakout chase.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock today.
Options Data
Neutral
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning/Sentiment: Open interest put-call ratio at 0.95 is roughly neutral (no strong skew), while the put-heavy option volume ratio at 1.13 leans mildly bearish/defensive in the very near term.
Volatility: 30D IV ~39% vs historical ~28.8%, with IV percentile ~93.6 (elevated). This signals the market is pricing meaningful near-term uncertainty (likely around upcoming catalysts/earnings). Options activity doesn’t show strong bullish conviction today, but it also doesn’t show panic-level hedging (OI PCR ~1).
Technical Summary
Sell
7
Buy
6
Positive Catalysts
Wall Street outlook improving: Multiple price target raises and upgrades (UBS to Buy; BofA to Buy; Piper reiterates Overweight) pointing to pipeline-driven “return to growth” visibility.
Pipeline/catalyst-rich setup for 2026: Several firms cite multiple near-term de-risking events.
Strategic partnership: Bristol Myers’ collaboration with Microsoft to enhance AI in healthcare (earlier lung cancer diagnosis) is a sentiment tailwind and supports longer-term innovation narrative.
Upcoming event: QDEC 2025 earnings on 2026-02-05 (pre-market) could act as a catalyst if results/guide reinforce the return-to-growth thesis.
Neutral/Negative Catalysts
Policy/price pressure risk: News notes CMS expanding Medicare drug price negotiation (including Part B), which can weigh on pharma pricing power and sentiment.
Insider behavior: Insiders are net sellers, with selling up sharply over the last month—often read as a near-term negative signal.
Congress trading: Last 90 days show 4 Congress trades, all sales (no buys), reinforcing a cautious tone.
Competitive backdrop (HCM): Commentary around Cytokinetics’ aficamten (Myqorzo) being positioned favorably vs BMY’s Camzyos is a competitive overhang in that niche.
Financial Performance
Latest quarter (2025/Q3): Revenue $12.222B (+2.77% YoY) shows modest top-line growth. Profitability improved sharply: Net income $2.201B (+81.75% YoY) and EPS $1.08 (+80% YoY). Gross margin rose to 66.1 (+18.57% YoY). Overall, Q3 2025 indicates improving earnings power and margin expansion—supportive for a long-term buy case even if revenue growth is not rapid.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Analyst sentiment has improved materially from mid-Dec 2025 into late Jan 2026, featuring multiple price target raises and notable upgrades.
Key changes: UBS upgraded to Buy with PT $65 (from $46). BofA upgraded to Buy with PT $61 (from $52). Piper maintained Overweight and raised PT to $66 (from $62). Citi and Scotiabank raised PTs (to ~$60 range) but remain Neutral/Sector Perform.
Wall Street pros: ‘Inexpensive’ setup vs perceived risks, better pipeline visibility, multiple 2026 catalysts, and a path to renewed growth later in the decade.
Wall Street cons: Ongoing LOE concerns (notably Eliquis over time), policy/pricing uncertainty, and selective competitive risks in certain franchises (e.g., Camzyos landscape).
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37 USD and a high forecast of 68 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37 USD and a high forecast of 68 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 55.560
Low
37
Averages
55.86
High
68
Current: 55.560
Low
37
Averages
55.86
High
68
Piper Sandler
Overweight
maintain
$62 -> $66
AI Analysis
2026-01-28
New
Reason
Piper Sandler
Price Target
$62 -> $66
AI Analysis
2026-01-28
New
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on Bristol Myers to $66 from $62 and keeps an Overweight rating on the shares. The firm says Bristol continues to profile as inexpensive, with the shares essentially pricing in the eventual Eliquis U.S. LOE, but not adequately reflecting what in Piper's view is growing visibility into a return to growth on the back of steady pipeline advancement.
Citi
Geoff Meacham
Neutral
maintain
$53 -> $60
2026-01-27
New
Reason
Citi
Geoff Meacham
Price Target
$53 -> $60
2026-01-27
New
maintain
Neutral
Reason
Citi analyst Geoff Meacham raised the firm's price target on Bristol Myers to $60 from $53 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are "beatable" and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BMY
